![Femoropopliteal Drug-Eluting Versus Bare-Metal Stents: Lost a BATTLE, But Not the War!∗ | JACC: Cardiovascular Interventions Femoropopliteal Drug-Eluting Versus Bare-Metal Stents: Lost a BATTLE, But Not the War!∗ | JACC: Cardiovascular Interventions](https://www.jacc.org/cms/asset/087a3ae4-0c68-4a00-bc7b-8a41766c2aad/fx1.jpg)
Femoropopliteal Drug-Eluting Versus Bare-Metal Stents: Lost a BATTLE, But Not the War!∗ | JACC: Cardiovascular Interventions
![ESPRIT I Bioresorbable Vascular Scaffold 30-Day Study Results: An Interview with Johannes Lammer, MD ESPRIT I Bioresorbable Vascular Scaffold 30-Day Study Results: An Interview with Johannes Lammer, MD](https://s3.amazonaws.com/HMP/hmp_ln/imported/uploads/JohannesLammer.png)
ESPRIT I Bioresorbable Vascular Scaffold 30-Day Study Results: An Interview with Johannes Lammer, MD
![Resurrection and development of V8 Project GT1 - Esprit 'Project & Restoration' Room - The Lotus Forums - Official Lotus Community Partner Resurrection and development of V8 Project GT1 - Esprit 'Project & Restoration' Room - The Lotus Forums - Official Lotus Community Partner](https://www.thelotusforums.com/forums/uploads/monthly_2019_03/GT1_small2.jpg.22119195d22f80c48e139b8d391a4c50.jpg)
Resurrection and development of V8 Project GT1 - Esprit 'Project & Restoration' Room - The Lotus Forums - Official Lotus Community Partner
![Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I): 2-Year Clinical and Imaging Results - ScienceDirect Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I): 2-Year Clinical and Imaging Results - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1936879816301339-gr1.jpg)
Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I): 2-Year Clinical and Imaging Results - ScienceDirect
![Resurrection and development of V8 Project GT1 - Esprit 'Project & Restoration' Room - The Lotus Forums - Official Lotus Community Partner Resurrection and development of V8 Project GT1 - Esprit 'Project & Restoration' Room - The Lotus Forums - Official Lotus Community Partner](https://www.thelotusforums.com/forums/uploads/monthly_2019_03/GT1_small1.jpg.90ddf335b95fc4996427e2570d29ce39.jpg)
Resurrection and development of V8 Project GT1 - Esprit 'Project & Restoration' Room - The Lotus Forums - Official Lotus Community Partner
![2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary - Brott - 2013 - Catheterization and Cardiovascular Interventions ... 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary - Brott - 2013 - Catheterization and Cardiovascular Interventions ...](https://onlinelibrary.wiley.com/cms/asset/02e257c7-5cbe-4c0c-99e2-3044d8c0a789/ccd.22983.fp.png)
2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary - Brott - 2013 - Catheterization and Cardiovascular Interventions ...
![Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I): 2-Year Clinical and Imaging Results - ScienceDirect Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I): 2-Year Clinical and Imaging Results - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1936879816301339-gr4.jpg)
Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I): 2-Year Clinical and Imaging Results - ScienceDirect
Commentary: All That Glitters Is Not Zilver: Promises and Disappointments of Endovascular Devices for Superficial Femoral Artery Disease - Laura Gatto, Giacomo Frati, Giuseppe Biondi-Zoccai, Arturo Giordano, 2018
![Less Is More: Developments in Nanotechnology for Antirestenosis Therapies | Arteriosclerosis, Thrombosis, and Vascular Biology Less Is More: Developments in Nanotechnology for Antirestenosis Therapies | Arteriosclerosis, Thrombosis, and Vascular Biology](https://www.ahajournals.org/cms/asset/ef39bc4b-5987-4c74-85c5-e8b11035de65/atvbaha.123.318450.fig05.jpg)